- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07227545
Høyintensitets vekselstrømstimulering som en neuromoduleringsterapi for alkoholbrukslidelse: En pilotstudie (HITACS-AUD)
Høyintensitet vekselstrømstimulering som en nevromoduleringsterapi for alkoholbrukslidelse: En pilotstudie
This one-arm pilot study aims to evaluate the preliminary clinical, behavioral, and neurophysiological effects of high-intensity transcranial alternating current stimulation (HI-tACS) in individuals with alcohol use disorder (AUD). Participants will receive HI-tACS and undergo clinical and neurophysiological assessments before and after the intervention.
Studieoversikt
Detaljert beskrivelse
Alcohol use disorder (AUD) has become a major social and public health problem. Persistent alcohol craving, impaired self-control, and abnormalities in decision-making and inhibitory control are important clinical and cognitive features of AUD. High-intensity transcranial alternating current stimulation (HI-tACS) is a non-invasive neuromodulation approach that may have potential therapeutic effects in individuals with AUD. However, its clinical and neurobiological effects in AUD remain unclear. The investigators hypothesize that HI-tACS may reduce alcohol craving and improve self-regulation and cognitive-control functions in individuals with AUD. This one-arm pilot study aims to evaluate the preliminary effects and tolerability of a 2-week course of HI-tACS, using clinical assessments together with electroencephalographic, and magnetic resonance imaging measures to explore potential changes in craving, self-control, risky decision-making, inhibitory control, and related neural activity. This study may provide preliminary clinical and mechanistic evidence for the further development of HI-tACS as a potential intervention for AUD.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Jiang Du, MD, PhD.
- Telefonnummer: +8602164906315
- E-post: dujiangdou@163.com
Studiesteder
-
-
-
Shanghai, Kina
- Rekruttering
- Shanghai Mental Health Center
-
Ta kontakt med:
- Jiang Du, MD, PhD.
- Telefonnummer: +86 021 6490 6315
- E-post: dujiangdou@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Education level of junior high school or above, capable of completing questionnaires and behavioral tests;
- Aged 18-60 years;
- Meet DSM-5 diagnostic criteria for Alcohol Use Disorder;
- No abnormal findings on physical examination;
- Agree to participate in follow-up assessments;
- No contraindications for MRI scanning.
Exclusion criteria:
- Have impaired intelligence (Intelligence Quotient<70);
- Prior tDCS or TMS treatment within the past 3 months;
- Contraindications for TMS therapy (e.g., intracranial metal implants, history of traumatic brain injury, skull defects, cardiac pacemakers, cardiovascular diseases, or epilepsy);
- Severe somatic diseases or major organ dysfunction;
- Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders).
- Psychiatric disorders per DSM-5 criteria (e.g., schizophrenia, schizoaffective disorder, intellectual disability, autism spectrum disorder, dementia, memory impairment, or other cognitive disorders).
- Diagnosis of other substance-related and addictive disorders or behavioral addictions.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: HI-tACS
A 40-minute 15mA transcranial alternating current stimulus intervention with 77.5 Hz of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of AUD. |
A 40-minute 15mA transcranial alternating current stimulus intervention with 77.5 Hz of real stimulus is conducted twice a day (at least 3 hours apart) for a total of 10 days in the intervention group of AUD. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The change of alcohol craving
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Alcohol craving will be measured by the alcohol craving Visual Analog Scale (VAS). The total score of VAS ranged from 0 to 10, in which higher scores mean a higher level of alcohol craving. |
Baseline, immediately after completion of the 2-week intervention
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The change of drinking urge
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Alcohol urge will be assessed using the Alcohol Urge Questionnaire (AUQ). The total score of AUQ ranges from 8 to 56, with higher scores indicating stronger urges to consume alcohol. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the compulsive drinking behavior
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Compulsive drinking behavior will be measured by the short form of the Obsessive-Compulsive Drinking Scale (OCDS). The total score of OCDS ranges from 0 to 40, with higher scores reflecting greater obsessive-compulsive thoughts and behaviors related to alcohol use. |
Baseline, immediately after completion of the 2-week intervention
|
|
Side effects of the modulation
Tidsramme: Immediately after each of the 20 HI-tACS sessions during the 2-week intervention period
|
Side effects will be assessed using a standardized adverse reaction evaluation form. The presence and severity of stimulation-related adverse reactions will be recorded for each symptom. |
Immediately after each of the 20 HI-tACS sessions during the 2-week intervention period
|
|
Change of depressive symptoms.
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Depressive symptoms will be measured using the 17-item Hamilton Depression Rating Scale (HAMD-17). The total score ranges from 0 to 52, with higher scores indicating more severe depressive symptoms. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of anxiety symptoms
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Anxiety symptoms will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14). The total score ranges from 0 to 56, where higher scores reflect greater anxiety severity. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the self-control ability
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Self-control ability will be measured using the Self-Control Scale (SCS). The total score ranges from 19 to 95, with higher scores of SCS indicating better self-regulation and impulse control. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the risky decision-making performance
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Risky decision-making will be assessed using the Balloon Analogue Risk Task (BART), with task performance and concurrent electroencephalography (EEG) measures related to risk-taking, decision-making, and outcome processing recorded. In addition, the Pig Dice Game will be administered during functional magnetic resonance imaging (fMRI) to assess risk-taking decision-making and associated task-related brain activity. Behavioral and neuroimaging measures derived from these tasks will be used to characterize changes in risk-related decision-making. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the inhibitory control performance
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Inhibitory control will be assessed using the Stop-Signal Task (SST), with task performance evaluated together with concurrent electroencephalography (EEG) measures related to response inhibition and inhibitory control. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the resting state neural activity.
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Resting-state functional magnetic resonance imaging (rsfMRI) will be used to assess intrinsic brain activity and functional connectivity. Resting-state electroencephalography (rsEEG) will be employed to assess spontaneous neural oscillatory activity. |
Baseline, immediately after completion of the 2-week intervention
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Individualized Electric Field Simulation
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
Individualized head models will be constructed using structural magnetic resonance imaging (sMRI), including T1-weighted imaging and diffusion tensor imaging (DTI). The electric field induced by HI-tACS will be simulated to characterize its spatial distribution and interindividual variability in modeled stimulation exposure. |
Baseline, immediately after completion of the 2-week intervention
|
|
Change of the molecular-level neurochemistry
Tidsramme: Baseline, immediately after completion of the 2-week intervention
|
SPICE magnetic resonance spectroscopic imaging will be used to explore changes in brain neurochemical profiles following HI-tACS. Metabolite-related signals and their spatial distributions will be assessed to characterize potential intervention-associated neurochemical alterations. Individual metabolite measurements will be analyzed separately, with their respective quantification methods and measurement units reported. |
Baseline, immediately after completion of the 2-week intervention
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- JDu-016
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .